A phase II study of maintenance S-1 after induction therapy of platinum doublet chemotherapy in patients with squamous cell carcinoma of the lung

A phase II study of maintenance S-1 after induction therapy of platinum doublet chemotherapy in patients with squamous cell carcinoma of the lung - A phase II study of maintenance S-1 after induction therapy of platinum doublet chemotherapy in patients with squamous cell carcinoma of the lung

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005702

Enrollment

Registered

2011-06-01

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

squamous cell carcinoma of the lung

Interventions

S-1 Maintenance

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Sqamous cell carcinoma of the lung was confirmed cytological or pathological examiation. 2. stage IIIB or IV and reccurent cases after resection. 3. age 20-80 years 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. 5. tumor with negative or unkown for EGFR senstive mutation. 6. CR, PR, and SD cases after induction platinum doublet.

Exclusion criteria

Exclusion criteria: they had a concurrent malignancy, uncontrollable complications, severe morbidity; hypersensitivity to therapeutic agents; the possibility of being pregnant, and other conditions such as hepatic inflammation, as judged by the attending physician.

Design outcomes

Primary

Measure	Time frame
PFS	—

Secondary

Measure	Time frame
RR(Maintenance),OS(MST), compliance (Maintenance), TS, DPD OPRT(5-Fu related molecules) AE	—

Countries

Japan

Contacts

Public ContactKoji Kuroda

University of Occupational and Environmental Health Second Department of Surgery

kuroda-k@med.uoeh-u.ac.jp0936917442

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026